© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
December 23, 2021
Expert perspective on clinical and personal improvements in cancer care made available by appropriate use of comprehensive genomic profiling.
David Gandara, MD, focuses on the differences between liquid biopsy and tissue-based CGP, suggesting a role for both in the current treatment landscape.
December 22, 2021
Jennifer Brigitte Green, MD, reviews her treatment approach for managing patients with type 2 diabetes and shares insight on how to identify patients that are uncontrolled with oral antidiabetic agents.
December 20, 2021
Drs Shah and Lio explore where topical ruxolitinib fits into therapeutic sequencing in atopic dermatitis, compared with oral JAK inhibitors.
Dr Lio discusses features that make JAK inhibitors, including ruxolitinib, abrocitinib, baricitinib, and upadacitinib, attractive in the management of atopic dermatitis.
December 14, 2021
Variables considered when developing and referring to treatment formularies for atopic dermatitis.
December 10, 2021
A clinical expert shared insight on the evolution of comprehensive genomic profiling and how it has impacted cancer care.
December 06, 2021
An overview of topical and oral therapies used to treat mild-to-moderate atopic dermatitis.
Considerations for quality measures established for atopic dermatitis when assessing how well patients are responding to treatment.